STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Page 2 / Line 8	Abstract/Methods
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2-3	Abstract
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4-5	Introduction
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 5 / Line 11-13	Introduction/last paragraph
Methods				
Study design	4	Present key elements of study design early in the paper	Page 5 / Line 16-22	Method/ Study design
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6 / Line 1-13	Method/Participants
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	Page 6 / Line 4-13	Method/ Participants
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 6 / Line 15-23, Page 7 / Line 1-20	Method/Procedure
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 6 / Line 15-23, Page 7 / Line 1-20	Method/Procedure
Bias	9	Describe any efforts to address potential sources of bias	Page 6 / Line 5	Participants / Paragraph 2
Study size	10	Explain how the study size was arrived at	Page 6 / Line 8-10	Participants / Paragraph 2
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 6 / Line 15-23, Page 7 / Line 1-20	Method/Procedure
Statistical methodsot	12	(*a*) Describe all statistical methods, including those used to control for confounding	Page 7 / Line22-24 Page 8 / Line 1-5	Method/Statistical analysis

		(*b*) Describe any methods used to examine subgroups and interactions	N/A	Did not perform the subgroup analysis and confounding effect.
		(*c*) Explain how missing data were addressed	N/A	There are no missing data.
		(*d*) If applicable, describe analytical methods taking account of sampling strategy	Page 6 / Line 8-10	Method /Paragraph 2
		(*e*) Describe any sensitivity analyses	Page 8 / Line 1	Methods / Statistical analysis
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 8 / Line 8-12	Participants / Paragraph 1
		(b) Give reasons for non-participation at each stage	Page 8 / Line 8-12	Participants / Paragraph 1
		(c) Consider use of a flow diagram	Figure 3	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 8 / Line 13-18	Results / Paragraph 2
		(b) Indicate number of participants with missing data for each variable of interest	N/A	There are no missing data.
Outcome data	15*	Report numbers of outcome events or summary measures	Page 8 / Line 21-23 Page 9 / Line 1-17	Results/ Paragraph 3-5
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 8 / Line 21-23 Page 9 / Line 1-17	Results/ Paragraph 3-5
		(*b*) Report category boundaries when continuous variables were categorized	N/A	Did not transform the continuous variables
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Page 8 / Line 21-23 Page 9 / Line 1-17	Results/ Paragraph 3-5

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	Did not perform other analysis
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 9 /Line 19-23 Page 10 / Line 1-18	Discussion / Paragraph 1-3
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 13 / Line 5 Page 13 / Line 5-7	Discussion
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 9 / Line 19-23 Page 10-13 / Line 1-23 Page 14 /Line 1-2	Discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 13 / Line 7	Discussion
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 14 / Line 11-13	Acknowledgements

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: http://dx.doi.org/10.21037/gs-20-466.

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.